abstract: UNASSIGNED: The aim of this study was to verify the presence of @entity817 mutations in a series of six @entity1 affected by drug-resistant @entity1625 associated with @entity7667 (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of @entity302 and represent the most common @entity5 in young @entity1 undergoing surgery for intractable @entity1625 . @entity817 mutations have been identified in up to 50% of GG. Interestingly, these six @entity1 shared a specific anatomical posterior temporal site. In all @entity1 , histological examination confirmed the diagnosis of GG, and two were also associated with a @entity10067 ( @entity10067 ) type IIa. @entity817 mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of @entity1 2 showed a concomitant @entity817 @entity8554 mutation. All @entity1 but one (83.3%) achieved Engel Class Ia @entity410 control. The @entity1 carrying a concomitant @entity817 mutation in GG and @entity10067 fell into Engel Class II. Further analyses will be required in order to better understand the meaning of @entity817 mutations in @entity5 and @entity10067 and their possible role as a prognostic @entity410 outcome and @entity5 behavior marker.

title: @entity817 XXXX mutation in neocortical posterior temporal @entity7667 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Patient']

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['focal epilepsy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'epilepsy-associated tumors']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity10067 :: ('MESH:C537067', 'Disease') :: ['FCD', 'focal cortical dysplasia']

entities_list: @entity7667 :: ('MESH:D018303', 'Disease') :: ['neocortical posterior temporal gangliogliomas']

answer: @entity8554 :: (p|SUB|V|600|E,ProteinMutation) :: ['V600E']


abstract: UNASSIGNED: The aim of this study was to verify the presence of @entity817 mutations in a series of six @entity1 affected by drug-resistant @entity1625 associated with @entity7667 (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of @entity302 and represent the most common @entity5 in young @entity1 undergoing surgery for intractable @entity1625 . @entity817 mutations have been identified in up to 50% of GG. Interestingly, these six @entity1 shared a specific anatomical posterior temporal site. In all @entity1 , histological examination confirmed the diagnosis of GG, and two were also associated with a @entity10067 ( @entity10067 ) type IIa. @entity817 mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of @entity1 2 showed a concomitant @entity817 @entity8554 mutation. All @entity1 but one (83.3%) achieved Engel Class Ia @entity410 control. The @entity1 carrying a concomitant @entity817 mutation in GG and @entity10067 fell into Engel Class II. Further analyses will be required in order to better understand the meaning of @entity817 mutations in @entity5 and @entity10067 and their possible role as a prognostic @entity410 outcome and @entity5 behavior marker.

title: @entity817 @entity8554 mutation in neocortical posterior temporal XXXX .

answer: @entity7667 :: (MESH:D018303,Disease) :: ['epileptogenic gangliogliomas']


abstract: UNASSIGNED: The aim of this study was to verify the presence of @entity817 mutations in a series of six @entity1 affected by drug-resistant @entity1625 associated with @entity7667 (GG) who were subjected to lesionectomy between June 2008 and November 2013. GG are an increasingly recognized cause of @entity302 and represent the most common @entity5 in young @entity1 undergoing surgery for intractable @entity1625 . @entity817 mutations have been identified in up to 50% of GG. Interestingly, these six @entity1 shared a specific anatomical posterior temporal site. In all @entity1 , histological examination confirmed the diagnosis of GG, and two were also associated with a @entity10067 ( @entity10067 ) type IIa. @entity817 mutations were found in four out of six GG (66.6%). Furthermore, dysplastic tissue of @entity1 2 showed a concomitant @entity817 @entity8554 mutation. All @entity1 but one (83.3%) achieved Engel Class Ia @entity410 control. The @entity1 carrying a concomitant @entity817 mutation in GG and @entity10067 fell into Engel Class II. Further analyses will be required in order to better understand the meaning of @entity817 mutations in @entity5 and @entity10067 and their possible role as a prognostic @entity410 outcome and @entity5 behavior marker.

title: XXXX @entity8554 mutation in neocortical posterior temporal @entity7667 .

answer: @entity817 :: (673,Gene) :: ['BRAF']


abstract: OBJECTIVE: This study assessed the impact of using a standardized definition of @entity5520 -related @entity89 (BRONJ) in the analysis of a spontaneous reporting database. METHODS: All notifications of @entity89 (ONJ) in the French National Pharmacovigilance Database as of 31 December 2013 were analyzed. First, we considered all reports of ONJ with @entity171 as BRONJ. Second, we applied the 2014 definition of BRONJ from the American Association of Oral and Maxillofacial Surgeons (AAOMS), retaining only @entity171 as antiresorptive medication. In the absence of any one of these criteria, or missing data, cases were not considered as BRONJ. RESULTS: The first analysis found 158 cases of ONJ, among which 153 were associated with @entity5520 use. The second analysis identified only 43 cases of BRONJ (28.1%). CONCLUSION: The definition of BRONJ as laid down by the AAOMS is not suitable for use in spontaneous reporting database. The use of the AAOMS definition alone should be avoided, as it leads to the exclusion of over 70% of cases. When cases of ONJ are identified, all results should be presented including confirmed and excluded cases.

title: Standardized classification unsuitable for spontaneous reporting: the example of XXXX .

entities_list: @entity5520 :: ('D004164', 'Chemical') :: ['bisphosphonate']

entities_list: @entity89 :: ('MESH:D007571', 'Disease') :: ['osteonecrosis of the jaw']

entities_list: @entity171 :: ('MESH:D004164', 'Chemical') :: ['bisphosphonates']

answer: @entity89 :: (MESH:D007571,Disease) :: ['osteonecrosis of the jaw']


abstract: BACKGROUND: ID polymorphism of the gene coding for the @entity1289 ( @entity1289 ) represents a determining factor in physical and athletic performance in the context of genetic conditioning of sports predisposition. The aim of this study was to show the potential importance of genetic factors in relation to the athletic status in Tunisian @entity2587 . METHODS: The @entity1289 genotypes were established using polymerase chain reaction (PCR) amplification for 282 Tunisian @entity2587 (endurance: N.=149 - power: N.=133), and 211 sedentary volunteers. RESULTS: No significant difference was found in the @entity1289 genotype distribution between @entity2587 (36% DD, 49% ID, 15% II) and controls (CTR) (39% DD, 46% ID, 15% II; P=0.72). In contrast, a high significant difference between endurance and power groups were noted in genotype and alleles (  2=10.32, P=0.0057;   2=4,752, P=0.029, respectively). The elite endurance- @entity2587 (N.=72) possess some inherent genetic advantage predisposing them to superior athletic performances compared to CTR for @entity1289 alleles (  2=3.51, P=0.06). In addition endurance trained @entity2587 were also significantly different from CTR for @entity1289 genotype (  2=6.05, P=0.04). Furthermore, a significant difference have been found between elite power- @entity2587 (N.=59) and CTR for @entity1289 alleles (  2=3.79, P=0.05). CONCLUSIONS: Tunisian @entity2587 exhibit insertion (I) and deletion (D) alleles of the @entity1289 polymorphism associated with a high level of @entity1 endurance and power performance, respectively. This genetic background plays an important role in sporting potential and causes some individuals to be better adapted to specific physical training. This should be considered in athlete development to identify which sporting specialties should be trained for Tunisian talent promotion.

title: Genetic advantageous predisposition of angiotensin converting enzyme id polymorphism in Tunisian XXXX .

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin I-converting enzyme', 'ACE']

answer: @entity2587 :: (MESH:D001265,Disease) :: ['athletes']


abstract: OBJECTIVE: The purpose of this study was to access the efficacy of mesenchymal stem cells (MSCs) injection in the treatment of @entity626 ( @entity571 ). METHODS: Studies were identified from databases (Pubmed, Embase, Cochrane Library, Biosis Previews, ClincalTrials.gov, CBMdisc) searched to December 2014 using a battery of keywords. We included randomized controlled and controlled clinical trials of @entity1 with knee @entity571 comparing the outcomes of @entity158 and function for those receiving MSCs injection with those receiving no MSCs injection. Two reviewers independently selected studies, extracted relevant data and assessed study quality. Data were pooled and meta-analyses were performed. RESULTS: Seven randomized controlled and controlled clinical trials, studying a total of 314 @entity1 with a diagnosis of knee @entity571 were included. Overall, MSCs injection has no significant effect on @entity158 [ @entity353 ( @entity353 ) (95 % confidence interval (CI)) [-1.33(-3.08, 0.41), P = 0.13], and tends to improve self-reported physical function [standardized mean difference (SMD) (CI) = 2.35(0.92, 3.77), P = 0.001] at the last follow-up. But results from two high quality trials (94 @entity1 ) show a positive effect of MSCs injection on @entity158 [ @entity353 (CI)   =   -0.49 (-0.79, -0.19), P = 0.001]. Heterogeneity observed between studies regarding the effect of MSCs injection on @entity158 and function was explained by the difference of follow-up time, outcome measures, control group, the source and dose of MSCs. The quality of evidence supporting these effect estimates was rated as low. CONCLUSION: MSCs injection could be potentially efficacious for decreasing @entity158 and may improve physical function in @entity1 with knee @entity571 . The findings of this review should be confirmed using methodologically rigorous and adequately powered clinical trials.

title: Efficacy of mesenchymal stem cells injection for the management of XXXX : a systematic review and meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'people']

entities_list: @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['WMD', 'weighted mean difference']

answer: @entity626 :: (MESH:D020370,Disease) :: ['knee osteoarthritis']


abstract: OBJECTIVES: To characterize outcomes of @entity1 experiencing a fall and subsequent @entity173 while in a nursing home receiving @entity1957 ( @entity1957 ) services. DESIGN: Observational study. @entity1 : Short-stay fee-for-service Medicare beneficiaries who experienced their first @entity173 during an @entity1957 stay. MEASUREMENTS: Outcomes measured in the 90  days after the @entity173 hospitalization included community discharge (with a stay in the community <30  days), successful community discharge (in the community >= 30  days), @entity204 , and institutionalization. RESULTS: Between 1999 and 2007, 27,305 @entity173 occurred among short-stay nursing home @entity1 receiving @entity1957 care. After surgical repair of the @entity173 , 83.9% of these @entity1 were discharged from the hospital back to an @entity1957 , with most (99%) returning to the facility where the @entity173 occurred. In the first 90  days after hospitalization, 24.1% of @entity1 died, 7.3% were discharged to the community but remained fewer than 30  days, 14.0% achieved successful community discharge, and 54.6% were still in a health care institution with almost 46.4% having transitioned to long-term care. CONCLUSION: @entity1957 care aims to maximize the short-stay @entity1 's independence and facilitate a safe community transition. However, experiencing a fall and @entity173 during the @entity1957 stay was a sentinel event that limited the achievement of this goal. There is an urgent need to ensure the integration of fall prevention into the @entity1 's plan of care. Further, falls among @entity1957 @entity1 may serve as indicator of quality, which consumers and payers can use to make informed health care decisions.

title: What Happens to XXXX When They Fracture Their Hip During a Skilled Nursing Facility Stay?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS']

entities_list: @entity173 :: ('MESH:D006620', 'Disease') :: ['hip fractures', 'hip fracture']

entities_list: @entity1957 :: ('MESH:D019957', 'Disease') :: ['SNF', 'skilled nursing facility']

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: PURPOSE: To evaluate the effect of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) on @entity3034 -induced peak-dose @entity910 in @entity1 with @entity191 ( @entity191 ). MATERIALS AND METHODS: A retrospective review was conducted on @entity1 who underwent STN DBS for @entity191 from May 2000 to July 2012. Only @entity1 with @entity3034 -induced @entity910 prior to surgery and more than 1 year of available follow-up data after DBS were included. The outcome measures included the @entity910 subscore of the Unified @entity191 Rating Scale (UPDRS) part IV (items 32 to 34 of UPDRS part IV) and the @entity3034 equivalent daily dose (LEDD). The @entity1 were divided into two groups based on preoperative to postoperative LEDD change at 12 months after the surgery: Group 1, LEDD decrease >15%; Group 2, all other @entity1 . Group 2 was further divided by the location of DBS leads. RESULTS: Of the 100 @entity1 enrolled, 67 were in Group 1, while those remaining were in Group 2. Twelve months after STN DBS, Groups 1 and 2 showed improvements of 61.90% and 57.14%, respectively, in the @entity910 subscore. Group 1 was more likely to experience @entity910 suppression; however, the association between the groups and @entity910 suppression was not statistically significant (p=0.619). In Group 2, @entity910 was significantly decreased by stimulation of the area above the STN in 18 @entity1 compared to stimulation of the STN in 15 @entity1 (p=0.048). CONCLUSION: @entity3034 -induced @entity910 is attenuated by STN DBS without reducing the @entity3034 dosage.

title: Effect of Subthalamic Deep Brain Stimulation on XXXX -Induced @entity910 in @entity191 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3034 :: ('MESH:D007980', 'Chemical') :: ['Levodopa', 'levodopa']

entities_list: @entity910 :: ('MESH:D004409', 'Disease') :: ['dyskinesia']

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", "Parkinson's Disease", 'PD']

answer: @entity3034 :: (MESH:D007980,Chemical) :: ['Levodopa']


abstract: PURPOSE: To evaluate the effect of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) on @entity3034 -induced peak-dose @entity910 in @entity1 with @entity191 ( @entity191 ). MATERIALS AND METHODS: A retrospective review was conducted on @entity1 who underwent STN DBS for @entity191 from May 2000 to July 2012. Only @entity1 with @entity3034 -induced @entity910 prior to surgery and more than 1 year of available follow-up data after DBS were included. The outcome measures included the @entity910 subscore of the Unified @entity191 Rating Scale (UPDRS) part IV (items 32 to 34 of UPDRS part IV) and the @entity3034 equivalent daily dose (LEDD). The @entity1 were divided into two groups based on preoperative to postoperative LEDD change at 12 months after the surgery: Group 1, LEDD decrease >15%; Group 2, all other @entity1 . Group 2 was further divided by the location of DBS leads. RESULTS: Of the 100 @entity1 enrolled, 67 were in Group 1, while those remaining were in Group 2. Twelve months after STN DBS, Groups 1 and 2 showed improvements of 61.90% and 57.14%, respectively, in the @entity910 subscore. Group 1 was more likely to experience @entity910 suppression; however, the association between the groups and @entity910 suppression was not statistically significant (p=0.619). In Group 2, @entity910 was significantly decreased by stimulation of the area above the STN in 18 @entity1 compared to stimulation of the STN in 15 @entity1 (p=0.048). CONCLUSION: @entity3034 -induced @entity910 is attenuated by STN DBS without reducing the @entity3034 dosage.

title: Effect of Subthalamic Deep Brain Stimulation on @entity3034 -Induced XXXX in @entity191 .

answer: @entity910 :: (MESH:D004409,Disease) :: ['Dyskinesia']


abstract: PURPOSE: To evaluate the effect of bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) on @entity3034 -induced peak-dose @entity910 in @entity1 with @entity191 ( @entity191 ). MATERIALS AND METHODS: A retrospective review was conducted on @entity1 who underwent STN DBS for @entity191 from May 2000 to July 2012. Only @entity1 with @entity3034 -induced @entity910 prior to surgery and more than 1 year of available follow-up data after DBS were included. The outcome measures included the @entity910 subscore of the Unified @entity191 Rating Scale (UPDRS) part IV (items 32 to 34 of UPDRS part IV) and the @entity3034 equivalent daily dose (LEDD). The @entity1 were divided into two groups based on preoperative to postoperative LEDD change at 12 months after the surgery: Group 1, LEDD decrease >15%; Group 2, all other @entity1 . Group 2 was further divided by the location of DBS leads. RESULTS: Of the 100 @entity1 enrolled, 67 were in Group 1, while those remaining were in Group 2. Twelve months after STN DBS, Groups 1 and 2 showed improvements of 61.90% and 57.14%, respectively, in the @entity910 subscore. Group 1 was more likely to experience @entity910 suppression; however, the association between the groups and @entity910 suppression was not statistically significant (p=0.619). In Group 2, @entity910 was significantly decreased by stimulation of the area above the STN in 18 @entity1 compared to stimulation of the STN in 15 @entity1 (p=0.048). CONCLUSION: @entity3034 -induced @entity910 is attenuated by STN DBS without reducing the @entity3034 dosage.

title: Effect of Subthalamic Deep Brain Stimulation on @entity3034 -Induced @entity910 in XXXX .

answer: @entity191 :: (MESH:D010300,Disease) :: ['Parkinson's Disease']


abstract: PURPOSE: Leptomeningeal collateral, in @entity7025 ( @entity7025 ), appears as an ivy sign on fluid-attenuated inversion-recovery (FLAIR) images. There has been little investigation into the relationship between presentation of ivy signs and old @entity75 . We aimed to evaluate clinical significance of ivy signs and whether they correlate with old @entity75 and the severity of clinical symptoms in @entity1 with @entity7025 . MATERIALS AND METHODS: FLAIR images of 83 @entity1 were reviewed. Each cerebral hemisphere was divided into 4 regions and each region was scored based on the prominence of the ivy sign. Total ivy score (TIS) was defined as the sum of the scores from the eight regions and dominant hemispheric ivy sign (DHI) was determined by comparing the ivy scores from each hemisphere. According to the degree of @entity63 , @entity1 were classified into four subgroups: 1) nonspecific symptoms without motor weakness, 2) single @entity63 ( @entity63 ), 3) recurrent @entity63 , or 4) @entity64 . RESULTS: TIS was significantly different as follows: 4.86  2.55 in @entity1 with nonspecific symptoms, 5.89  3.10 in @entity1 with single @entity63 , 9.60  3.98 in @entity1 with recurrent @entity63 and 8.37  3.39 in @entity1 with @entity64 (p=0.003). TIS associated with old lesions was significantly higher than those not associated with old lesions (9.35  4.22 vs. 7.49  3.37, p=0.032). We found a significant correlation between DHI and motor symptoms (p=0.001). CONCLUSION: Because TIS has a strong tendency with severity of @entity63 motor symptom and the presence of old lesions, the ivy sign may be useful in predicting severity of disease progression.

title: Ivy Sign on Fluid-Attenuated Inversion Recovery Images in Moyamoya Disease: Correlation with Clinical Severity and Old XXXX .

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['complete stroke']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['transient ischemic attack', 'ischemic symptoms', 'TIA', 'ischemic']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain lesions']

entities_list: @entity7025 :: ('MESH:D009072', 'Disease') :: ['moyamoya disease', 'MMD']

answer: @entity75 :: (MESH:D001927,Disease) :: ['Brain Lesions']


abstract: PURPOSE: The purpose of this study is to explore the influence of segmentation of the upstream and downstream parent artery and hemodynamic boundary conditions (BCs) on the evaluated hemodynamic factors for the @entity5173 ( @entity5173 ) analysis of @entity438 . MATERIALS AND METHODS: Three dimensional @entity1 -specific @entity439 models were analyzed by applying various combinations of inlet and outlet BCs. Hemodynamic factors such as velocity pattern, streamline, wall shear stress, and oscillatory shear index at the systolic time were visualized and compared among the different cases. RESULTS: Hemodynamic factors were significantly affected by the inlet BCs while there was little influence of the outlet BCs. When the inlet length was relatively short, different inlet BCs showed different hemodynamic factors and the calculated hemodynamic factors were also dependent on the inlet length. However, when the inlet length (L) was long enough (L>20D, where D is the diameter of inlet section), the hemodynamic factors became similar regardless of the inlet BCs and lengths. The error due to different inlet BCs was negligible. The effect of the outlet length on the hemodynamic factors was similar to that of the inlet length. CONCLUSION: Simulated hemodynamic factors are highly sensitive to inlet BCs and upstream parent artery segmentation. The results of this work can provide an insight into how to build models and to apply BCs for more accurate estimation of hemodynamic factors from @entity5173 simulations of @entity438 .

title: Influence of Parent Artery Segmentation and Boundary Conditions on Hemodynamic Characteristics of XXXX .

entities_list: @entity5173 :: ('MESH:D065634', 'Disease') :: ['CFD', 'computational fluid dynamics']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysms']

answer: @entity438 :: (MESH:D002532,Disease) :: ['Intracranial Aneurysms']


abstract: OBJECTIVE: This study investigated multidimensional treatment outcomes, including prognostic factors and side effects of vocal fold @entity479 injection (VFSI). METHODS: We recruited 126 consecutive @entity1 , including @entity1 with 49 nodules, 47 @entity1127 , and 30 mucus retention cysts. All the @entity1 received VFSI under local anesthesia in the office settings. Treatment outcomes were evaluated 1 and 2 months after the procedure, including endoscopic evaluation, @entity132 (GRB scores), acoustic analysis, and 10-item Voice Handicap Index (VHI-10). RESULTS: More than 80% of the @entity1 reported subjective improvements after VFSI. Objective measurements revealed significant improvements from baseline in most of the outcome parameters (P<0.05). Higher occupational vocal demands and fibrotic vocal nodules were significantly associated with poorer clinical responses as measured by the VHI-10 and GRB scores, respectively. For vocal @entity1127 , @entity7364 for more than 12 months were significantly associated with higher postoperative VHI-10 scores, whereas @entity1 with @entity8823 ( @entity8823 ) showed significantly poor postoperative voice quality as measured by GRB scores. Side effects after VFSI included @entity1410 (27%), @entity2713 deposits (4%), and vocal @entity194 (1%), which resolved spontaneously within 1-2 months. Presentation with vocal fold @entity4122 /varicosities and higher vocal demands were significantly correlated with postoperative vocal @entity1410 . CONCLUSIONS: This study demonstrated significant improvements after VFSI in vocal nodules, @entity1127 , and cysts. Occupational vocal demand and subtypes of vocal nodules are closely related to the treatment outcomes after VFSI, whereas symptom duration and @entity8823 were significant prognostic factors for VFSI treatment outcomes in vocal @entity1127 . Side effects after receiving VFSI were mostly self-limited without sequel, whereas the incidence rates might be varied by the injection approach and the timing for postoperative follow-up.

title: Comprehensive Outcome Researches of Intralesional XXXX Injection on Benign Vocal Fold Lesions.

entities_list: @entity2713 :: ('MESH:D014221', 'Chemical') :: ['triamcinolone']

entities_list: @entity132 :: ('MESH:D010468', 'Disease') :: ['perceptual voice quality']

entities_list: @entity7364 :: ('MESH:D055154', 'Disease') :: ['dysphonia']

entities_list: @entity8823 :: ('MESH:D057045', 'Disease') :: ['LPR', 'laryngopharyngeal reflux']

answer: @entity479 :: (D013256,Chemical) :: ['Steroid']


abstract: UNASSIGNED: @entity72 ( @entity72 ) are characterized by social communication deficits, @entity73 , and repetitive stereotyped behaviors. Mesenchymal stem cells (MSC) have a paracrine regenerative effect, and were speculated to be a potential therapy for @entity72 . The BTBR inbred @entity19 is a commonly used model of @entity72 as it demonstrates robust behavioral deficits consistent with the diagnostic criteria for @entity72 . BTBR @entity19 also exhibit decreased @entity9140 ( @entity9140 ) signaling and reduced hippocampal neurogenesis. In the current study, we evaluated the behavioral and molecular effects of intracerebroventricular  MSC transplantation in BTBR @entity19 . Transplantation of MSC resulted in a reduction of stereotypical behaviors, a decrease in @entity73 and an improvement in social behavior. Tissue analysis revealed elevated @entity9140 protein levels in the hippocampus accompanied by increased hippocampal neurogenesis in the MSC-transplanted @entity19 compared with sham treated @entity19 . This might indicate a possible mechanism underpinning the behavioral improvement. Our study suggests a novel therapeutic approach which may be translatable to @entity72 @entity1 in the future. @entity2438 Res 2015.    2015 International Society for @entity2438 Research, Wiley Periodicals, Inc.

title: Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates XXXX Related Behaviors in BTBR @entity19 .

entities_list: @entity9140 :: ('12064(Tax:10090)', 'Gene') :: ['brain-derived neurotrophic factor', 'BDNF']

entities_list: @entity19 :: ('10090', 'Species') :: ['mice', 'mouse strain']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive rigidity']

entities_list: @entity72 :: ('MESH:D002659', 'Disease') :: ['ASD', 'Autism spectrum disorders']

answer: @entity2438 :: (MESH:D001321,Disease) :: ['Autism']


abstract: UNASSIGNED: @entity72 ( @entity72 ) are characterized by social communication deficits, @entity73 , and repetitive stereotyped behaviors. Mesenchymal stem cells (MSC) have a paracrine regenerative effect, and were speculated to be a potential therapy for @entity72 . The BTBR inbred @entity19 is a commonly used model of @entity72 as it demonstrates robust behavioral deficits consistent with the diagnostic criteria for @entity72 . BTBR @entity19 also exhibit decreased @entity9140 ( @entity9140 ) signaling and reduced hippocampal neurogenesis. In the current study, we evaluated the behavioral and molecular effects of intracerebroventricular  MSC transplantation in BTBR @entity19 . Transplantation of MSC resulted in a reduction of stereotypical behaviors, a decrease in @entity73 and an improvement in social behavior. Tissue analysis revealed elevated @entity9140 protein levels in the hippocampus accompanied by increased hippocampal neurogenesis in the MSC-transplanted @entity19 compared with sham treated @entity19 . This might indicate a possible mechanism underpinning the behavioral improvement. Our study suggests a novel therapeutic approach which may be translatable to @entity72 @entity1 in the future. @entity2438 Res 2015.    2015 International Society for @entity2438 Research, Wiley Periodicals, Inc.

title: Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates @entity2438 Related Behaviors in BTBR XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity19 :: (10090,Species) :: ['Mice']


abstract: OBJECTIVE: To evaluate fixation and @entity1019 characteristics among subjects with @entity6 in a population-based study. DESIGN: Cohort study. @entity1 : A subset of 357 subjects was recruited from follow-up cohort of Sankara Nethralaya @entity6 Epidemiology and Molecular Genetics Study I. METHODS: All subjects underwent detailed ophthalmic evaluation including microperimetry and spectral domain optical coherence tomography. Fixation parameters such as stability of fixation, fixation location, and presence of @entity1019 were evaluated. A p value less than 0.05 was considered statistically significant. RESULTS: The mean age of the study sample was 56.86    8.63 years. Relatively unstable fixation was observed in 73 and poor central fixation in 25 subjects. Among subjects with poor central fixation, 72% (18 subjects) had relatively unstable fixation. Poor central and relatively unstable fixation were significantly associated with best corrected visual acuity (BCVA; p = 0.002 and p = 0.017, respectively). Prevalence rate of @entity1019 was 24.4%, which was highly prevalent in females (p = 0.035) and among subjects with reduced BCVA (p < 0.001), reduced contrast sensitivity (p < 0.001), @entity231 (p < 0.001), @entity989 (p < 0.001), and presence of sight-threatening @entity6 (STDR; p < 0.001). Presence of @entity1019 was significantly associated with abnormal foveal contour (p = 0.046) and altered inner retinal layers (p < 0.001). CONCLUSIONS: We report that fixation characteristics are independent of ocular characteristics except for BCVA. Female sex, reduced visual acuity and contrast sensitivity, @entity231 , and STDR were significantly associated with presence of @entity1019 .

title: Fixation characteristics among subjects with XXXX : SN-DREAMS II, Report No. 5.

entities_list: @entity1 :: ('9606', 'Species') :: ['PARTICIPANTS']

entities_list: @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy', 'diabetes', 'diabetic retinopathy']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['impaired retinal sensitivity']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: AIMS: To evaluate safety, efficacy and @entity413 turnover during closed-loop with meal announcement using reduced prandial @entity2690 boluses in adolescents with @entity1723 ( @entity1723 ). METHODS: We conducted a randomized crossover study comparing closed-loop therapy with standard prandial @entity2690 boluses versus closed-loop therapy with prandial boluses reduced by 25%. Eight adolescents with @entity1723 [3 males; mean (standard deviation) age 15.9 (1.5) years, glycated haemoglobin 74 (17) mmol/mol; median (interquartile range) total daily dose 0.9 (0.7, 1.1) IU/kg/day] were studied on two 36-h-long visits. In random order, subjects received closed-loop therapy with either standard or reduced @entity2690 boluses administered with main meals (50-80 g @entity3363 ) but not with snacks (15-30 g @entity3363 ). Stable-label tracer dilution methodology measured total @entity413 appearance (Ra_total) and @entity413 disposal (Rd). RESULTS: The median (interquartile range) time spent in target (3.9-10 mmol/l) was similar between the two interventions [74 (66, 84)% vs 80 (65, 96)%; p = 0.87] as was time spent above 10 mmol/l [21.8 (16.3, 33.5)% vs 18.0 (4.1, 34.2)%; p = 0.87] and below 3.9 mmol/l [0 (0, 1.5)% vs 0 (0, 1.8)%; p = 0.88]. Mean plasma @entity413 was identical during the two interventions [8.4 (0.9) mmol/l; p = 0.98]. Hypoglycaemia occurred once 1.5 h post-meal during closed-loop therapy with standard bolus. Overall @entity2690 delivery was lower with reduced prandial boluses [61.9 (55.2, 75.0) vs 72.5 (63.6, 80.3) IU; p = 0.01] and resulted in lower mean plasma @entity2690 concentration [186 (171, 260) vs 252 (198, 336) pmol/l; p = 0.002]. Lower plasma @entity2690 was also documented overnight [160 (136, 192) vs 191 (133, 252) pmol/l; p = 0.01, pooled nights]. Ra_total was similar [26.3 (21.9, 28.0) vs 25.4 (21.0, 29.2)   mol/kg/min; p = 0.19] during the two interventions as was Rd [25.8 (21.0, 26.9) vs 25.2 (21.2, 28.8)   mol/kg/min; p = 0.46]. CONCLUSIONS: A 25% reduction in prandial boluses during closed-loop therapy maintains similar @entity413 control in adolescents with @entity1723 whilst lowering overall plasma @entity2690 levels. It remains unclear whether closed-loop therapy with a 25% reduction in prandial boluses would prevent @entity4053 .

title: Safety, efficacy and @entity413 turnover of reduced prandial boluses during closed-loop therapy in adolescents with XXXX : a randomized clinical trial.

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['postprandial hypoglycaemia']

entities_list: @entity1723 :: ('MESH:D003922', 'Disease') :: ['T1D', 'type 1 diabetes']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity3363 :: ('MESH:D002241', 'Chemical') :: ['carbohydrates']

answer: @entity1723 :: (MESH:D003922,Disease) :: ['type 1 diabetes']


abstract: AIMS: To evaluate safety, efficacy and @entity413 turnover during closed-loop with meal announcement using reduced prandial @entity2690 boluses in adolescents with @entity1723 ( @entity1723 ). METHODS: We conducted a randomized crossover study comparing closed-loop therapy with standard prandial @entity2690 boluses versus closed-loop therapy with prandial boluses reduced by 25%. Eight adolescents with @entity1723 [3 males; mean (standard deviation) age 15.9 (1.5) years, glycated haemoglobin 74 (17) mmol/mol; median (interquartile range) total daily dose 0.9 (0.7, 1.1) IU/kg/day] were studied on two 36-h-long visits. In random order, subjects received closed-loop therapy with either standard or reduced @entity2690 boluses administered with main meals (50-80 g @entity3363 ) but not with snacks (15-30 g @entity3363 ). Stable-label tracer dilution methodology measured total @entity413 appearance (Ra_total) and @entity413 disposal (Rd). RESULTS: The median (interquartile range) time spent in target (3.9-10 mmol/l) was similar between the two interventions [74 (66, 84)% vs 80 (65, 96)%; p = 0.87] as was time spent above 10 mmol/l [21.8 (16.3, 33.5)% vs 18.0 (4.1, 34.2)%; p = 0.87] and below 3.9 mmol/l [0 (0, 1.5)% vs 0 (0, 1.8)%; p = 0.88]. Mean plasma @entity413 was identical during the two interventions [8.4 (0.9) mmol/l; p = 0.98]. Hypoglycaemia occurred once 1.5 h post-meal during closed-loop therapy with standard bolus. Overall @entity2690 delivery was lower with reduced prandial boluses [61.9 (55.2, 75.0) vs 72.5 (63.6, 80.3) IU; p = 0.01] and resulted in lower mean plasma @entity2690 concentration [186 (171, 260) vs 252 (198, 336) pmol/l; p = 0.002]. Lower plasma @entity2690 was also documented overnight [160 (136, 192) vs 191 (133, 252) pmol/l; p = 0.01, pooled nights]. Ra_total was similar [26.3 (21.9, 28.0) vs 25.4 (21.0, 29.2)   mol/kg/min; p = 0.19] during the two interventions as was Rd [25.8 (21.0, 26.9) vs 25.2 (21.2, 28.8)   mol/kg/min; p = 0.46]. CONCLUSIONS: A 25% reduction in prandial boluses during closed-loop therapy maintains similar @entity413 control in adolescents with @entity1723 whilst lowering overall plasma @entity2690 levels. It remains unclear whether closed-loop therapy with a 25% reduction in prandial boluses would prevent @entity4053 .

title: Safety, efficacy and XXXX turnover of reduced prandial boluses during closed-loop therapy in adolescents with @entity1723 : a randomized clinical trial.

answer: @entity413 :: (MESH:D005947,Chemical) :: ['glucose']


abstract: BACKGROUND AND AIMS: Conivaptan, a @entity1951 receptor antagonist, is commonly used for the treatment of euvolaemic, hypervolaemic hyponatraemia. Usually, an intravenous (IV) bolus followed by infusion is administered for many days. We decided to assess the effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative @entity1 . METHODS: This was a prospective, randomised trial conducted in 40 symptomatic post-operative Intensive Care Unit (ICU) @entity1 with a serum @entity1372 level of  <=130 mEq/L. Group A @entity1 received IV @entity15707 20 mg over 30 min, whereas in group B infusion of 3% hypertonic saline was started as an infusion at the rate of 20-30 ml/h. Serum @entity1372 levels were measured at 12, 24, 48 and 72 h and the daily fluid balance was measured for 3 days. The Chi-square test, Wilcoxon signed rank test and Mann-Whitney tests were used as applicable. RESULTS: The serum @entity1372 levels before initiating treatment were comparable between groups. However, subsequent @entity1372 levels at 12, 24 and 48 h showed significantly high values in group A. Though at 72 h the mean @entity1372 value was high in group A, it was not statistically significant. Group A showed a significantly high fluid loss on day 1, 2 and 3. The mean volume of hypertonic saline required in group B showed a steady decline from day 1 to 3 and only 13 @entity1 required hypertonic saline on the 3(rd) day. CONCLUSION: Single dose conivaptan is effective in increasing serum @entity1372 levels in post-operative ICU @entity1 up to 72 h associated with a significant negative fluid balance.

title: Effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative XXXX following major head and neck surgeries.

entities_list: @entity1951 :: ('MESH:D014667', 'Chemical') :: ['vasopressin']

entities_list: @entity15707 :: ('MESH:C106389', 'Chemical') :: ['conivaptan']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Evidence supports the efficacy of pharmacy services in @entity2175 ( @entity2175 ). However, little is known about consumer perspectives on the role of community pharmacists in @entity6 care. The objectives of this study were to identify potential unmet needs and explore preferences for pharmacist-delivered support for @entity2175 . METHODS: A qualitative study using focus groups was conducted in Sydney, Australia. @entity1 with @entity2175 who were members of the Australian @entity6 Council in Sydney, Australia, were recruited through a survey on medication use in @entity2175 . Five focus groups with a total of 32 consumers with @entity2175 were recorded, transcribed, and thematically analyzed. RESULTS: The key themes were 1) the experiences of @entity6 services received, 2) the potential to deliver self-management services, and 3) the suggested role of pharmacist in supporting @entity6 management. Gaps in understanding and some degree of nonadherence to self-management signaled a potential for self-management support delivered by pharmacists. However, consumers still perceive that the main role of pharmacists in @entity6 care centers on drug management services, with some enhancements to support adherence and continuity of supply. Barriers to @entity6 care services included time constraints and a perceived lack of interest by pharmacists. CONCLUSION: Given the unmet needs in @entity6 self-management, opportunities exist for pharmacists to be involved in @entity6 care. The challenge is for pharmacists to upgrade their @entity6 knowledge and skills, organize their workflow, and become proactive in delivering @entity6 care support.

title: Supporting self-management of XXXX : is there a role for the community pharmacist?

entities_list: @entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

answer: @entity2175 :: (MESH:D003924,Disease) :: ['type 2 diabetes']


abstract: Whilst @entity8 , especially mild impairment (60< @entity470 <90 ml/min), has been often described in @entity645 -infected population, its potential contribution to @entity645 evolution and risk of @entity65 ( @entity65 ) has not been clarified. Data from @entity2858 infected @entity1 enrolled in the Italian Cohort of Antiretroviral-Na  ve (Icona) Foundation Study collected between January 2000 and February 2014 with at least two creatinine values available. @entity470 (CKD-epi) and @entity8 defined using a priori cut-offs of 60 (severely impaired) and 90 ml/min/1.73m2 (mildly impaired). Characteristics of @entity1 were described after stratification in these groups and compared using chi-square test (categorical variables) or Kruskal Wallis test comparing median values. Follow-up accrued from baseline up to the date of the @entity65 or @entity791 related events or @entity204 or last available visit. Kaplan Meier curves were used to estimate the cumulative probability of occurrence of the events over time. Adjusted analysis was performed using a proportional hazards Cox regression model. We included 7,385 @entity1 , observed for a median follow-up of 43 months (inter-quartile range [IQR]: 21-93 months). Over this time, 130 cerebro-cardiovascular events (including 11 @entity204 due to @entity65 ) and 311 @entity791 -related events (including 45 @entity204 ) were observed. The rate of @entity65 events among @entity1 with @entity470 >90, 60-89, <60 ml/min, was 2.91 (95% CI 2.30-3.67), 4.63 (95% CI 3.51-6.11) and 11.9 (95% CI 6.19-22.85) per 1,000 PYFU respectively, with an unadjusted hazard ratio (HR) of 4.14 (95%CI 2.07-8.29) for @entity1 with @entity470 <60 ml/min and 1.58 (95%CI 1.10-2.27) for @entity470 60-89 compared to those with @entity470 >= 90. Of note, these estimates are adjusted for traditional cardio-vascular risk factors (e.g. smoking, @entity6 , @entity101 , @entity2299 ). Incidence of @entity791 -related events was 9.51 (95%CI 8.35-10.83), 6.04 (95%CI 4.74-7.71) and 25.0 (95%CI 15.96-39.22) per 1,000 PYFU, among @entity1 with @entity470 >90, 60-89, <60 ml/min, respectively, with an unadjusted HR of 2.49 (95%CI 1.56-3.97) for @entity1 with @entity470 <60 ml/min and 0.68 (95%CI 0.52-0.90) for @entity470 60-89. The risk of @entity791 events was significantly lower in mild @entity8 group even after adjustment for @entity645 -related characteristics. Our data confirm that @entity8 is an important risk marker for @entity65 events in the @entity645 -population; importantly, even those with mild @entity8 (90< @entity470 <60) seem to be at increased risk of cerebro-cardiovascular morbidity and mortality.

title: Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of XXXX -Infected @entity1 Seen for Care in Italy.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal impairment', 'renal dysfunction', 'impaired renal function']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['CCVD', 'cerebro-cardiovascular disease']

answer: @entity645 :: (57667,Species) :: ['HIV']


abstract: Whilst @entity8 , especially mild impairment (60< @entity470 <90 ml/min), has been often described in @entity645 -infected population, its potential contribution to @entity645 evolution and risk of @entity65 ( @entity65 ) has not been clarified. Data from @entity2858 infected @entity1 enrolled in the Italian Cohort of Antiretroviral-Na  ve (Icona) Foundation Study collected between January 2000 and February 2014 with at least two creatinine values available. @entity470 (CKD-epi) and @entity8 defined using a priori cut-offs of 60 (severely impaired) and 90 ml/min/1.73m2 (mildly impaired). Characteristics of @entity1 were described after stratification in these groups and compared using chi-square test (categorical variables) or Kruskal Wallis test comparing median values. Follow-up accrued from baseline up to the date of the @entity65 or @entity791 related events or @entity204 or last available visit. Kaplan Meier curves were used to estimate the cumulative probability of occurrence of the events over time. Adjusted analysis was performed using a proportional hazards Cox regression model. We included 7,385 @entity1 , observed for a median follow-up of 43 months (inter-quartile range [IQR]: 21-93 months). Over this time, 130 cerebro-cardiovascular events (including 11 @entity204 due to @entity65 ) and 311 @entity791 -related events (including 45 @entity204 ) were observed. The rate of @entity65 events among @entity1 with @entity470 >90, 60-89, <60 ml/min, was 2.91 (95% CI 2.30-3.67), 4.63 (95% CI 3.51-6.11) and 11.9 (95% CI 6.19-22.85) per 1,000 PYFU respectively, with an unadjusted hazard ratio (HR) of 4.14 (95%CI 2.07-8.29) for @entity1 with @entity470 <60 ml/min and 1.58 (95%CI 1.10-2.27) for @entity470 60-89 compared to those with @entity470 >= 90. Of note, these estimates are adjusted for traditional cardio-vascular risk factors (e.g. smoking, @entity6 , @entity101 , @entity2299 ). Incidence of @entity791 -related events was 9.51 (95%CI 8.35-10.83), 6.04 (95%CI 4.74-7.71) and 25.0 (95%CI 15.96-39.22) per 1,000 PYFU, among @entity1 with @entity470 >90, 60-89, <60 ml/min, respectively, with an unadjusted HR of 2.49 (95%CI 1.56-3.97) for @entity1 with @entity470 <60 ml/min and 0.68 (95%CI 0.52-0.90) for @entity470 60-89. The risk of @entity791 events was significantly lower in mild @entity8 group even after adjustment for @entity645 -related characteristics. Our data confirm that @entity8 is an important risk marker for @entity65 events in the @entity645 -population; importantly, even those with mild @entity8 (90< @entity470 <60) seem to be at increased risk of cerebro-cardiovascular morbidity and mortality.

title: Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of @entity645 -Infected XXXX Seen for Care in Italy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity1 :: (9606,Species) :: ['People']


abstract: Bacteria are known to cope with environmental changes by using alternative sigma factors binding to RNA polymerase core enzyme. Sigma factor is one of the targets to modify transcription regulation in bacteria and to influence production capacities. In this study, the effect of overexpressing each annotated sigma factor gene in @entity9150 WT was assayed using an @entity6874 inducible plasmid system and different @entity6874 concentrations. It was revealed that growth was severely decreased when sigD or sigH were overexpressed with @entity6874 concentrations higher than 50  M. Overexpression of sigH led to an obvious phenotypic change, a yellow-colored supernatant. High performance liquid chromatography analysis revealed that @entity8728 was excreted to the medium when sigH was overexpressed and DNA microarray analysis confirmed increased expression of @entity8728 biosynthesis genes. In addition, genes for enzymes related to the @entity36435 pathway and for enzymes dependent on @entity10698 ( @entity10698 ), @entity10697 ( @entity10697 ), or @entity1110 as cofactor were upregulated when sigH was overexpressed. To test if sigH overexpression can be exploited for production of @entity8728 -derived @entity10698 or @entity10697 , the endogenous gene for bifunctional @entity8728 kinase/ @entity10698 adenyltransferase was co-expressed with sigH from a plasmid. Balanced expression of sigH and ribF improved accumulation of @entity8728 (19.8    0.3  M) and allowed for its conversion to @entity10698 (33.1    1.8  M) in the supernatant. While a proof-of-concept was reached, conversion was not complete and titers were not high. This study revealed that inducible and gradable overexpression of sigma factor genes is an interesting approach to switch gene expression profiles and to discover untapped potential of bacteria for chemical production.

title: Exploring the role of sigma factor gene expression on production by @entity9150 : sigma factor H and XXXX as example.

entities_list: @entity9150 :: ('1718', 'Species') :: ['Corynebacterium glutamicum']

entities_list: @entity10698 :: ('MESH:D005486', 'Chemical') :: ['flavin mononucleotide', 'FMN']

entities_list: @entity36435 :: ('D010428', 'Chemical') :: ['pentose phosphate']

entities_list: @entity10697 :: ('MESH:D005182', 'Chemical') :: ['flavin adenine dinucleotide', 'FAD']

entities_list: @entity8728 :: ('MESH:D012256', 'Chemical') :: ['riboflavin']

answer: @entity10698 :: (MESH:D005486,Chemical) :: ['FMN']


abstract: Bacteria are known to cope with environmental changes by using alternative sigma factors binding to RNA polymerase core enzyme. Sigma factor is one of the targets to modify transcription regulation in bacteria and to influence production capacities. In this study, the effect of overexpressing each annotated sigma factor gene in @entity9150 WT was assayed using an @entity6874 inducible plasmid system and different @entity6874 concentrations. It was revealed that growth was severely decreased when sigD or sigH were overexpressed with @entity6874 concentrations higher than 50  M. Overexpression of sigH led to an obvious phenotypic change, a yellow-colored supernatant. High performance liquid chromatography analysis revealed that @entity8728 was excreted to the medium when sigH was overexpressed and DNA microarray analysis confirmed increased expression of @entity8728 biosynthesis genes. In addition, genes for enzymes related to the @entity36435 pathway and for enzymes dependent on @entity10698 ( @entity10698 ), @entity10697 ( @entity10697 ), or @entity1110 as cofactor were upregulated when sigH was overexpressed. To test if sigH overexpression can be exploited for production of @entity8728 -derived @entity10698 or @entity10697 , the endogenous gene for bifunctional @entity8728 kinase/ @entity10698 adenyltransferase was co-expressed with sigH from a plasmid. Balanced expression of sigH and ribF improved accumulation of @entity8728 (19.8    0.3  M) and allowed for its conversion to @entity10698 (33.1    1.8  M) in the supernatant. While a proof-of-concept was reached, conversion was not complete and titers were not high. This study revealed that inducible and gradable overexpression of sigma factor genes is an interesting approach to switch gene expression profiles and to discover untapped potential of bacteria for chemical production.

title: Exploring the role of sigma factor gene expression on production by XXXX : sigma factor H and @entity10698 as example.

answer: @entity9150 :: (1718,Species) :: ['Corynebacterium glutamicum']


abstract: The site of outflow resistance leading to elevated intraocular pressure in primary @entity1538 is believed to be located in the region of Schlemm's canal inner wall endothelium, its basement membrane and the adjacent juxtacanalicular tissue. Evidence also suggests collector channels and intrascleral vessels may have a role in intraocular pressure in both normal and @entity726 eyes. Traditional imaging modalities limit the ability to view both proximal and distal portions of the trabecular outflow pathway as a single unit. In this study, we examined the effectiveness of three-dimensional micro-computed tomography (3D micro-CT) as a potential method to view the trabecular outflow pathway. Two normal @entity1 eyes were used: one immersion fixed in 4% @entity1604 and one with anterior chamber perfusion at 10  mmHg followed by perfusion fixation in 4% @entity1604 /2% @entity3584 . Both eyes were postfixed in 1% @entity3734 and scanned with 3D micro-CT at 2   m or 5   m voxel resolution. In the immersion fixed eye, 24 collector channels were identified with an average orifice size of 27.5      5   m. In comparison, the perfusion fixed eye had 29 collector channels with a mean orifice size of 40.5      13   m. Collector channels were not evenly dispersed around the circumference of the eye. There was no significant difference in the length of Schlemm's canal in the immersed versus the perfused eye (33.2 versus 35.1  mm). Structures, locations and size measurements identified by 3D micro-CT were confirmed by correlative light microscopy. These findings confirm 3D micro-CT can be used effectively for the non-invasive examination of the trabecular meshwork, Schlemm's canal, collector channels and intrascleral vasculature that comprise the distal outflow pathway. This imaging modality will be useful for non-invasive study of the role of the trabecular outflow pathway as a whole unit.

title: Imaging the aqueous humor outflow pathway in XXXX eyes by three-dimensional micro-computed tomography (3D micro-CT).

entities_list: @entity3734 :: ('MESH:D009993', 'Chemical') :: ['osmium tetroxide']

entities_list: @entity1538 :: ('MESH:D005902', 'Disease') :: ['open-angle glaucoma']

entities_list: @entity3584 :: ('MESH:D005976', 'Chemical') :: ['glutaraldehyde']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma']

entities_list: @entity1604 :: ('MESH:C003043', 'Chemical') :: ['paraformaldehyde']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: OBJECTIVES: To identify circumstances surrounding the onset of @entity174 and common risk factors in @entity1 with @entity1566 ( @entity1566 ) and to suggest an alternative or complement to the pharmacologic approach by evaluating the need for a prospective study based on the impact of a targeted therapeutic education on risk management of @entity174 in this population. DESIGN: Retrospective study. SETTING: Hospital and Rehabilitation Center Setting. @entity1 : @entity1 (n=7) and @entity1 (n=25; N=32; with >= 1 @entity174 after the initial @entity1566 that occurred at home or in a hospital setting; mean    SD age, 53  12y at the time of clinical review) with bone mineral density (BMD) measurements. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Demographics, main circumstances of onset, and complications of @entity174 , as well as transversal bone mineral density evaluation. RESULTS: Nine @entity1 had more than 1 @entity174 and 23 @entity1 had only 1 @entity174 (total, 43 @entity174 ; mean age at onset of @entity174 , 49  12y; median time since injury, 13.9y; mean delay in diagnosis, 6.5  15d). @entity174 occurred mostly in the lower limbs. The circumstances of onset of these @entity174 were different and very stereotyped. In 3 cases, no @entity130 was reported. The most frequent mechanisms identified were forced maneuvers by the @entity1 or a third party and falls. In 10 cases, the @entity174 occurred during a wheelchair transfer with forced maneuver or a fall from the wheelchair. Twenty-five @entity1 were confined to bed after the @entity174 (mean duration of bed confinement, 18  28d; range, 0-120d). Postfracture follow-up showed that for 43 cases of @entity174 , 19 had at least 1 orthopedic complication, 15 had local complications, and 23 had general complications. @entity1 (23 of 32) benefited from dual-energy X-ray absorptiometry to assess BMD a few months or years after the @entity174 (mean femoral neck BMD, 0.574  0.197g/cm  ; mean femoral neck T score, -3.8  1.5). CONCLUSION: With this retrospective analysis of common risk factors and circumstances of onset of secondary @entity174 , there is a clear future for a prospective study to evaluate the impact of targeted therapeutic education on risk factors for secondary @entity174 in @entity1 with @entity1566 .

title: Osteoporosis in @entity1 with XXXX : the need for a targeted therapeutic education.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Women', 'patient', 'PARTICIPANTS', 'persons', 'men']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury', 'SCI']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures', 'Fractures', 'fracture']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: OBJECTIVES: To identify circumstances surrounding the onset of @entity174 and common risk factors in @entity1 with @entity1566 ( @entity1566 ) and to suggest an alternative or complement to the pharmacologic approach by evaluating the need for a prospective study based on the impact of a targeted therapeutic education on risk management of @entity174 in this population. DESIGN: Retrospective study. SETTING: Hospital and Rehabilitation Center Setting. @entity1 : @entity1 (n=7) and @entity1 (n=25; N=32; with >= 1 @entity174 after the initial @entity1566 that occurred at home or in a hospital setting; mean    SD age, 53  12y at the time of clinical review) with bone mineral density (BMD) measurements. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: Demographics, main circumstances of onset, and complications of @entity174 , as well as transversal bone mineral density evaluation. RESULTS: Nine @entity1 had more than 1 @entity174 and 23 @entity1 had only 1 @entity174 (total, 43 @entity174 ; mean age at onset of @entity174 , 49  12y; median time since injury, 13.9y; mean delay in diagnosis, 6.5  15d). @entity174 occurred mostly in the lower limbs. The circumstances of onset of these @entity174 were different and very stereotyped. In 3 cases, no @entity130 was reported. The most frequent mechanisms identified were forced maneuvers by the @entity1 or a third party and falls. In 10 cases, the @entity174 occurred during a wheelchair transfer with forced maneuver or a fall from the wheelchair. Twenty-five @entity1 were confined to bed after the @entity174 (mean duration of bed confinement, 18  28d; range, 0-120d). Postfracture follow-up showed that for 43 cases of @entity174 , 19 had at least 1 orthopedic complication, 15 had local complications, and 23 had general complications. @entity1 (23 of 32) benefited from dual-energy X-ray absorptiometry to assess BMD a few months or years after the @entity174 (mean femoral neck BMD, 0.574  0.197g/cm  ; mean femoral neck T score, -3.8  1.5). CONCLUSION: With this retrospective analysis of common risk factors and circumstances of onset of secondary @entity174 , there is a clear future for a prospective study to evaluate the impact of targeted therapeutic education on risk factors for secondary @entity174 in @entity1 with @entity1566 .

title: Osteoporosis in XXXX with @entity1566 : the need for a targeted therapeutic education.

answer: @entity1 :: (9606,Species) :: ['persons']


abstract: BACKGROUND/OBJECTIVES: There are increasing evidences suggesting that chemotherapeutic agents can enhance the cytotoxic T lymphocytes (CTLs) antitumor effect, but the precise mechanism is not fully explained. This study aims to investigate whether @entity136 ( @entity14113 ) can sensitize @entity788 cells to the CTLs antitumor response, and explore the potential mechanism. METHODS: Cell counting kit-8 assays (CCK-8) were performed to determine the @entity5 cell proliferation. Flow cytometric analysis was conducted to analyze maturation of DCs and the expression of Fas. An @entity4404 FITC Apoptosis Detection Kit was performed to detect @entity5 cell apoptosis. CytoTox 96 Nonradioactive @entity137 assays were used to determine T cell-mediated @entity5 cell lysis. RESULTS: First, it was demonstrated that Bacillus Calmette Gu  rin (BCG) could be used to induce effective CTLs antitumor response. Then, @entity14113 inhibited the growth of @entity1 cells, induced apoptosis and upregulated the Fas expression even at a low concentration. When antagonistic anti-Fas mAb ZB4 was preincubated with @entity14113 -treated @entity1 cells, the lysis induced by CTLs was reduced. Moreover, agonistic anti-Fas mAb @entity10762 induced more apoptosis of @entity14113 -treated @entity1 cells. CONCLUSION: Our results show that @entity14113 sensitizes @entity788 cells to the CTLs antitumor response, and the sensitization is associated with upregulation of Fas on @entity788 cells.

title: @entity136 sensitizes XXXX cells to the CTLs antitumor  response induced by BCG-stimulated dendritic cells via  a  Fas-dependent pathway.

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['Cytotoxicity']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']


abstract: BACKGROUND/OBJECTIVES: There are increasing evidences suggesting that chemotherapeutic agents can enhance the cytotoxic T lymphocytes (CTLs) antitumor effect, but the precise mechanism is not fully explained. This study aims to investigate whether @entity136 ( @entity14113 ) can sensitize @entity788 cells to the CTLs antitumor response, and explore the potential mechanism. METHODS: Cell counting kit-8 assays (CCK-8) were performed to determine the @entity5 cell proliferation. Flow cytometric analysis was conducted to analyze maturation of DCs and the expression of Fas. An @entity4404 FITC Apoptosis Detection Kit was performed to detect @entity5 cell apoptosis. CytoTox 96 Nonradioactive @entity137 assays were used to determine T cell-mediated @entity5 cell lysis. RESULTS: First, it was demonstrated that Bacillus Calmette Gu  rin (BCG) could be used to induce effective CTLs antitumor response. Then, @entity14113 inhibited the growth of @entity1 cells, induced apoptosis and upregulated the Fas expression even at a low concentration. When antagonistic anti-Fas mAb ZB4 was preincubated with @entity14113 -treated @entity1 cells, the lysis induced by CTLs was reduced. Moreover, agonistic anti-Fas mAb @entity10762 induced more apoptosis of @entity14113 -treated @entity1 cells. CONCLUSION: Our results show that @entity14113 sensitizes @entity788 cells to the CTLs antitumor response, and the sensitization is associated with upregulation of Fas on @entity788 cells.

title: XXXX sensitizes @entity788 cells to the CTLs antitumor  response induced by BCG-stimulated dendritic cells via  a  Fas-dependent pathway.

answer: @entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']


abstract: MicroRNAs (miRs) are noncoding RNAs that regulate gene expression at the post-transcriptional level. In animals, the target sites of a @entity72090 are generally located in the 3' untranslated regions (UTRs) of messenger RNAs. However, how the target sites change during evolution is largely unknown. @entity72091 and @entity72091 as are known to regulate the expression of two @entity17809 genes, @entity4534 and @entity4564 , in @entity238 . We have therefore studied the evolutionary changes of these two @entity72090 genes and their target sites of the @entity17809 genes in @entity238 , other insect species, and Daphnia. Our homology search identified a single copy of each @entity72090 gene located in the same genomic position of the @entity17809 gene cluster in all species examined. The seed @entity377 sequence was also the same for all species. Searching for the target sites in all @entity17809 genes, we found several target sites of @entity72091 and @entity72091 as in @entity4565 in addition to @entity4534 and @entity4564 in most insect species examined. Our phylogenetic analysis of target sites in @entity4534 , @entity4564 , and @entity4565 showed that the old target sites, which existed before the divergence of the 12 @entity238 species, have been well maintained in most species under purifying selection. By contrast, new target sites, which were generated during @entity238 evolution, were often lost in some species and mostly located in unalignable regions of the 3' UTRs. These results indicate that these regions can be a potential source of generating new target sites, which results in multiple target genes for each @entity72090 in animals.

title: Evolutionary changes of the target sites of two microRNAs encoded in the XXXX gene cluster of @entity238 and other insect species.

entities_list: @entity377 :: ('CHEBI:36976', 'Chemical') :: ['nucleotide']

entities_list: @entity238 :: ('7227', 'Species') :: ['Drosophila melanogaster', 'Drosophila']

answer: @entity17809 :: (42536(Tax:7227),Gene) :: ['Hox']


abstract: MicroRNAs (miRs) are noncoding RNAs that regulate gene expression at the post-transcriptional level. In animals, the target sites of a @entity72090 are generally located in the 3' untranslated regions (UTRs) of messenger RNAs. However, how the target sites change during evolution is largely unknown. @entity72091 and @entity72091 as are known to regulate the expression of two @entity17809 genes, @entity4534 and @entity4564 , in @entity238 . We have therefore studied the evolutionary changes of these two @entity72090 genes and their target sites of the @entity17809 genes in @entity238 , other insect species, and Daphnia. Our homology search identified a single copy of each @entity72090 gene located in the same genomic position of the @entity17809 gene cluster in all species examined. The seed @entity377 sequence was also the same for all species. Searching for the target sites in all @entity17809 genes, we found several target sites of @entity72091 and @entity72091 as in @entity4565 in addition to @entity4534 and @entity4564 in most insect species examined. Our phylogenetic analysis of target sites in @entity4534 , @entity4564 , and @entity4565 showed that the old target sites, which existed before the divergence of the 12 @entity238 species, have been well maintained in most species under purifying selection. By contrast, new target sites, which were generated during @entity238 evolution, were often lost in some species and mostly located in unalignable regions of the 3' UTRs. These results indicate that these regions can be a potential source of generating new target sites, which results in multiple target genes for each @entity72090 in animals.

title: Evolutionary changes of the target sites of two microRNAs encoded in the @entity17809 gene cluster of XXXX and other insect species.

answer: @entity238 :: (7227,Species) :: ['Drosophila']


abstract: PURPOSE: To compare percutaneous transpedicular vertebroplasty using @entity78 cement (CPC) versus conservative treatment for @entity3604 . METHODS: Eight @entity1 and 28 @entity1 aged 61 to 99 (mean, 80) years with @entity3604 underwent percutaneous transpedicular vertebroplasty using CPC. During the same period, 6 @entity1 and 32 @entity1 aged 53 to 93 (mean, 77) years underwent conservative treatment. The indication for vertebroplasty was a @entity158 , with @entity6679 of the vertebral body shown on flexion and extension lateral radiographs. @entity174 without @entity6679 despite deformity were treated conservatively. RESULTS: In the vertebroplasty group, all @entity1 benefited from reduced back @entity158 immediately after surgery, and @entity158 relief was maintained at the latest follow-up. However, correction loss continued until one month after the operation. The mean visual analogue score for @entity158 decreased significantly from preoperation to one day after surgery (9.3 vs. 6.2, p=0.02), and further decreased to 2.8 (p = 0.04) on day 3 or 4 when ambulation began, and to 1.5 at the one month follow-up and 1.4 at the final follow-up (mean, 14 months). The mean duration of analgesic treatment was significantly shorter in the vertebroplasty than conservatively treated group (10.2 vs. 63.5 days). All @entity1 in the vertebroplasty group achieved bone union, with no adjacent @entity174 . However, in @entity1 having conservative treatment, there were 2 adjacent @entity174 and 4 @entity1516 , and the collapse continued for several months. CONCLUSION: Percutaneous transpedicular vertebroplasty using CPC achieves immediate @entity158 relief and reduces the risk of @entity891 and @entity1516 among elderly @entity1 with @entity3814 .

title: Percutaneous vertebroplasty for osteoporotic compression fractures using XXXX cement.

entities_list: @entity3604 :: ('MESH:D058866', 'Disease') :: ['osteoporotic vertebral fractures']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['vertebral fractures', 'Fractures']

entities_list: @entity78 :: ('MESH:C020243', 'Chemical') :: ['calcium phosphate']

entities_list: @entity3814 :: ('MESH:D050815', 'Disease') :: ['osteoporotic vertebral compression fractures']

entities_list: @entity891 :: ('MESH:D001261', 'Disease') :: ['vertebral body collapse']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['painful unstable fracture', 'pain']

entities_list: @entity1516 :: ('MESH:D011542', 'Disease') :: ['pseudarthrosis', 'pseudarthroses']

answer: @entity78 :: (MESH:C020243,Chemical) :: ['calcium phosphate']


abstract: AIM: The aim of this study was to evaluate functional and prognostic benefits of Doppler ultrasonography (DU), @entity8 ( @entity8 ), and magnetic resonance urography (MRU) during diagnosis and follow-up of @entity4145 ( @entity4145 ) and to examine apoptosis rates caused by @entity4145 in an experimental @entity95 model. METHOD: Twenty-four @entity95 were divided randomly into two groups. The left kidneys of 15 @entity95 from the first group underwent Ulm-Miller surgery to create @entity4145 , whereas the left kidneys of nine @entity95 from the second group underwent sham surgery. A pressure flow study (Whitaker's test) was done during postoperative week 6. Based on the Whitaker test, the DU, @entity8 , and MRU findings were compared. The number of apoptotic renal cells was counted after death. RESULT: The Whitaker test run during postoperative week 6 revealed @entity3885 in 15 @entity95 from group 1; the nine @entity95 of the sham group had no @entity3885 . Sensitivity and specificity of @entity8 were 93.3 and 88.8 %, respectively, and those of MRU were 93.3 and 88.8 %, respectively. The postoperative mean RI values were significantly higher than the preoperative values, associated with sensitivity of 86.6 % and specificity of 77.5 % for detecting @entity4145 . @entity8 , MRU, and RI could not predict @entity4145 in one (8 %), one (8 %), and two (16 %) kidneys, respectively. Likelihood ratio (LR) was 8.4 for MRU and scintigraphy, while for RI, LR was 3.9. Pathology specimens revealed that all kidneys with @entity4145 underwent apoptosis, and the number of apoptotic cells was significantly higher on the @entity4145 -created side than on the contralateral and in the sham group (p < 0.05). No test predicted all apoptosis related to @entity4145 . CONCLUSION: The RI, @entity8 , and DMRU results correlated with the pressure flow results for detecting @entity4145 . No single radiological technique predicted all initial @entity4145 -created kidneys that concluded with apoptosis. Further studies are required to seek with better methods for diagnosing an obstruction or to define a combination of radiological techniques aiding in the management decision.

title: Current radiological techniques used to evaluate unilateral partial ureteral obstruction: an experimental XXXX study.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['DRS', 'diuretic renal scintigraphy']

entities_list: @entity95 :: ('9986', 'Species') :: ['rabbits', 'rabbit']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstructions']

entities_list: @entity4145 :: ('MESH:C537373', 'Disease') :: ['ureteropelvic junction obstruction', 'UPJO']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: PURPOSE: To present the management and outcomes of blebitis in @entity1 who underwent EX-PRESS @entity726 ( @entity726 ) implantation. DESIGN: Retrospective case series. @entity1 : The study included 5 @entity1 who developed blebitis following EX-PRESS @entity726 implantation. METHODS: Charts of all @entity1 who underwent EX-PRESS @entity726 implantation at the @entity726 Center of San Francisco between 2007 and 2013 were reviewed. Five @entity1 with blebitis were identified and their clinical course was recorded. MAIN OUTCOME MEASURES: Clinical course of blebitis. RESULTS: Of 325 eyes that underwent EX-PRESS @entity726 implantation, 5 eyes (1.5%) with blebitis were identified. The mean interval between EX-PRESS @entity726 surgery and blebitis was 2.3  0.8 years. Four of the 5 eyes with blebitis had potential risk factors for @entity281 ; 1 had chronic @entity14985 , 2 had contact lens use, and one had 2 episodes of @entity4530 before blebitis. All @entity1 were treated with topical antibiotics; in addition, 3 received oral antibiotics and 1 received intravitreal antibiotics. None of the @entity1 developed @entity3225 . One @entity1 had recurrent blebitis, which was treated with topical, oral, and intravitreal antibiotics. None of the @entity1 had the device removed. The mean follow-up time after blebitis was 16.8  8.9 months (range, 10 to 32 mo). CONCLUSIONS: This case series suggests that blebitis after EX-PRESS @entity726 implanted under a scleral flap may be treated without removal of the device. Further study is required to determine the optimal method of treating this condition.

title: Blebitis After EX-PRESS XXXX Implantation-A Case Series.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS']

entities_list: @entity14985 :: ('MESH:D001762', 'Disease') :: ['blepharitis']

entities_list: @entity726 :: ('MESH:D005901', 'Disease') :: ['Glaucoma', 'GFD', 'Glaucoma Filtration Device']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['bleb-related infection']

entities_list: @entity3225 :: ('MESH:D009877', 'Disease') :: ['endophthalmitis']

answer: @entity726 :: (MESH:D005901,Disease) :: ['Glaucoma Filtration Device']


abstract: BACKGROUND: @entity5 @entity1 have a significantly higher risk of developing a @entity1211 ( @entity1211 ) compared to non- @entity5 @entity1 and yet studies suggest @entity1211 risk among @entity5 @entity1 varies widely. Recently, predictive models capable of risk-stratifying a broad range of @entity5 outpatients have been developed. Using the Khorana model a score of 2 was intermediate-high risk for @entity1211 as reported by Ay and colleagues. However, validation in a broader population and methods to implement this model seamlessly into clinical practice are lacking. OBJECTIVE: To create and assess the feasibility of an innovative computerized Care Process Management System (CPMS) that would automatically access electronic medical records to calculate in real-time the risk of @entity1211 in @entity1 with active @entity5 using an established @entity1211 risk scoring system. METHODS: A prospective observational study of all newly referred @entity5 @entity1 at the Ottawa @entity5 care provider for 1.2 million inhabitants, was conducted. RESULTS: 699 new referrals were determined to have a @entity5 diagnosis for the first time as identified by the computer software and qualified for our study and 580 were eligible. In total 25% had intermediate-high risk for @entity1211 and during the 3-month follow up period, 16 of the 143 (11%) developed a @entity1211 which further validates the Khorana model for identifying intermediate-high risk @entity1 . Of the 437 @entity1 in the low risk group 19 (4%) developed a @entity1211 . CONCLUSION: Newly diagnosed @entity5 @entity1 can be readily stratified into intermediate-high and low risk of @entity1211 using our novel CPMS system. This innovative tool can be used to facilitate customized management decisions regarding @entity1211 prophylaxis for intermediate-high risk @entity1 based their individual risk factors.

title: Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in XXXX @entity1 at intermediate-high risk for venous thrombosis.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['ambulatory cancer', 'Regional Cancer Center, the sole cancer', 'cancer', 'Cancer']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'venous thromboembolism']

answer: @entity5 :: (MESH:D009369,Disease) :: ['ambulatory cancer']


abstract: BACKGROUND: @entity5 @entity1 have a significantly higher risk of developing a @entity1211 ( @entity1211 ) compared to non- @entity5 @entity1 and yet studies suggest @entity1211 risk among @entity5 @entity1 varies widely. Recently, predictive models capable of risk-stratifying a broad range of @entity5 outpatients have been developed. Using the Khorana model a score of 2 was intermediate-high risk for @entity1211 as reported by Ay and colleagues. However, validation in a broader population and methods to implement this model seamlessly into clinical practice are lacking. OBJECTIVE: To create and assess the feasibility of an innovative computerized Care Process Management System (CPMS) that would automatically access electronic medical records to calculate in real-time the risk of @entity1211 in @entity1 with active @entity5 using an established @entity1211 risk scoring system. METHODS: A prospective observational study of all newly referred @entity5 @entity1 at the Ottawa @entity5 care provider for 1.2 million inhabitants, was conducted. RESULTS: 699 new referrals were determined to have a @entity5 diagnosis for the first time as identified by the computer software and qualified for our study and 580 were eligible. In total 25% had intermediate-high risk for @entity1211 and during the 3-month follow up period, 16 of the 143 (11%) developed a @entity1211 which further validates the Khorana model for identifying intermediate-high risk @entity1 . Of the 437 @entity1 in the low risk group 19 (4%) developed a @entity1211 . CONCLUSION: Newly diagnosed @entity5 @entity1 can be readily stratified into intermediate-high and low risk of @entity1211 using our novel CPMS system. This innovative tool can be used to facilitate customized management decisions regarding @entity1211 prophylaxis for intermediate-high risk @entity1 based their individual risk factors.

title: Implementation and validation of a risk stratification method at The Ottawa Hospital to guide thromboprophylaxis in @entity5 XXXX at intermediate-high risk for venous thrombosis.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: @entity19859 has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute @entity1778 could potentially improve outcomes. We conducted a phase II study of @entity1863 (.8 mg/kg i.v. twice daily on days  -5,  -4,  -3, and  -2) with @entity19859 (40 mg/m(2) i.v. daily on days  -5,  -4,  -3, and  -2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day  +40. Secondary endpoints included nonrelapse mortality (NRM), @entity2132 ( @entity2132 ), progression-free survival (PFS), and @entity1349 ( @entity1349 ). Thirty-four @entity1 ( @entity3052 [ @entity3052 ], n  = 25; @entity2590 , n  = 5; and @entity981 , n  = 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 @entity1 with 1 @entity1 dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic @entity2132 were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and @entity1349 was 56% (95% CI, 38 to 71). For @entity1 with @entity3052 in first complete remission, 2-year PFS and @entity1349 were both 82% (95% CI, 55 to 94). RIC with @entity1863 and @entity19859 leads to successful engraftment with acceptable rates of NRM and @entity2132 .

title: Phase II Trial of Reduced-Intensity XXXX / @entity19859 Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for @entity1 with @entity3052 , @entity2590 , and @entity981 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity981 :: ('MESH:D054198', 'Disease') :: ['acute lymphoid leukemia']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndromes']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'acute and chronic graft-versus-host disease']

entities_list: @entity1863 :: ('MESH:D002066', 'Chemical') :: ['busulfan']

entities_list: @entity19859 :: ('MESH:C068329', 'Chemical') :: ['Clofarabine', 'clofarabine']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1863 :: (MESH:D002066,Chemical) :: ['Busulfan']


abstract: UNASSIGNED: @entity19859 has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute @entity1778 could potentially improve outcomes. We conducted a phase II study of @entity1863 (.8 mg/kg i.v. twice daily on days  -5,  -4,  -3, and  -2) with @entity19859 (40 mg/m(2) i.v. daily on days  -5,  -4,  -3, and  -2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day  +40. Secondary endpoints included nonrelapse mortality (NRM), @entity2132 ( @entity2132 ), progression-free survival (PFS), and @entity1349 ( @entity1349 ). Thirty-four @entity1 ( @entity3052 [ @entity3052 ], n  = 25; @entity2590 , n  = 5; and @entity981 , n  = 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 @entity1 with 1 @entity1 dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic @entity2132 were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and @entity1349 was 56% (95% CI, 38 to 71). For @entity1 with @entity3052 in first complete remission, 2-year PFS and @entity1349 were both 82% (95% CI, 55 to 94). RIC with @entity1863 and @entity19859 leads to successful engraftment with acceptable rates of NRM and @entity2132 .

title: Phase II Trial of Reduced-Intensity @entity1863 / XXXX Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for @entity1 with @entity3052 , @entity2590 , and @entity981 .

answer: @entity19859 :: (MESH:C068329,Chemical) :: ['Clofarabine']


abstract: UNASSIGNED: @entity19859 has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute @entity1778 could potentially improve outcomes. We conducted a phase II study of @entity1863 (.8 mg/kg i.v. twice daily on days  -5,  -4,  -3, and  -2) with @entity19859 (40 mg/m(2) i.v. daily on days  -5,  -4,  -3, and  -2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day  +40. Secondary endpoints included nonrelapse mortality (NRM), @entity2132 ( @entity2132 ), progression-free survival (PFS), and @entity1349 ( @entity1349 ). Thirty-four @entity1 ( @entity3052 [ @entity3052 ], n  = 25; @entity2590 , n  = 5; and @entity981 , n  = 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 @entity1 with 1 @entity1 dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic @entity2132 were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and @entity1349 was 56% (95% CI, 38 to 71). For @entity1 with @entity3052 in first complete remission, 2-year PFS and @entity1349 were both 82% (95% CI, 55 to 94). RIC with @entity1863 and @entity19859 leads to successful engraftment with acceptable rates of NRM and @entity2132 .

title: Phase II Trial of Reduced-Intensity @entity1863 / @entity19859 Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for @entity1 with @entity3052 , @entity2590 , and XXXX .

answer: @entity981 :: (MESH:D054198,Disease) :: ['Acute Lymphoid Leukemia']


abstract: UNASSIGNED: @entity19859 has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute @entity1778 could potentially improve outcomes. We conducted a phase II study of @entity1863 (.8 mg/kg i.v. twice daily on days  -5,  -4,  -3, and  -2) with @entity19859 (40 mg/m(2) i.v. daily on days  -5,  -4,  -3, and  -2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day  +40. Secondary endpoints included nonrelapse mortality (NRM), @entity2132 ( @entity2132 ), progression-free survival (PFS), and @entity1349 ( @entity1349 ). Thirty-four @entity1 ( @entity3052 [ @entity3052 ], n  = 25; @entity2590 , n  = 5; and @entity981 , n  = 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 @entity1 with 1 @entity1 dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic @entity2132 were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and @entity1349 was 56% (95% CI, 38 to 71). For @entity1 with @entity3052 in first complete remission, 2-year PFS and @entity1349 were both 82% (95% CI, 55 to 94). RIC with @entity1863 and @entity19859 leads to successful engraftment with acceptable rates of NRM and @entity2132 .

title: Phase II Trial of Reduced-Intensity @entity1863 / @entity19859 Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for @entity1 with XXXX , @entity2590 , and @entity981 .

answer: @entity3052 :: (MESH:D015470,Disease) :: ['Acute Myeloid Leukemia']


abstract: UNASSIGNED: @entity19859 has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute @entity1778 could potentially improve outcomes. We conducted a phase II study of @entity1863 (.8 mg/kg i.v. twice daily on days  -5,  -4,  -3, and  -2) with @entity19859 (40 mg/m(2) i.v. daily on days  -5,  -4,  -3, and  -2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day  +40. Secondary endpoints included nonrelapse mortality (NRM), @entity2132 ( @entity2132 ), progression-free survival (PFS), and @entity1349 ( @entity1349 ). Thirty-four @entity1 ( @entity3052 [ @entity3052 ], n  = 25; @entity2590 , n  = 5; and @entity981 , n  = 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 @entity1 with 1 @entity1 dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic @entity2132 were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and @entity1349 was 56% (95% CI, 38 to 71). For @entity1 with @entity3052 in first complete remission, 2-year PFS and @entity1349 were both 82% (95% CI, 55 to 94). RIC with @entity1863 and @entity19859 leads to successful engraftment with acceptable rates of NRM and @entity2132 .

title: Phase II Trial of Reduced-Intensity @entity1863 / @entity19859 Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for @entity1 with @entity3052 , XXXX , and @entity981 .

answer: @entity2590 :: (MESH:D009190,Disease) :: ['Myelodysplastic Syndromes']


abstract: UNASSIGNED: @entity19859 has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute @entity1778 could potentially improve outcomes. We conducted a phase II study of @entity1863 (.8 mg/kg i.v. twice daily on days  -5,  -4,  -3, and  -2) with @entity19859 (40 mg/m(2) i.v. daily on days  -5,  -4,  -3, and  -2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day  +40. Secondary endpoints included nonrelapse mortality (NRM), @entity2132 ( @entity2132 ), progression-free survival (PFS), and @entity1349 ( @entity1349 ). Thirty-four @entity1 ( @entity3052 [ @entity3052 ], n  = 25; @entity2590 , n  = 5; and @entity981 , n  = 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 @entity1 with 1 @entity1 dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic @entity2132 were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and @entity1349 was 56% (95% CI, 38 to 71). For @entity1 with @entity3052 in first complete remission, 2-year PFS and @entity1349 were both 82% (95% CI, 55 to 94). RIC with @entity1863 and @entity19859 leads to successful engraftment with acceptable rates of NRM and @entity2132 .

title: Phase II Trial of Reduced-Intensity @entity1863 / @entity19859 Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for XXXX with @entity3052 , @entity2590 , and @entity981 .

answer: @entity1 :: (9606,Species) :: ['Patients']


abstract: UNASSIGNED: @entity5 ( @entity5 ) is an endemic type of @entity135 with a high rate of cervical lymph node @entity3 . An increasing number of studies have shown that microRNAs (miRNAs) play a key role in the development and progression of @entity5 . miR-338-3p has been demonstrated as an anti-oncogene in different @entity5 . The aim of the present study was to investigate the potential role of miR  -338-3p in the development and progression of @entity5 . Compared with normal samples, our data showed that miR-338-3p were downregulated in @entity5 tissues and cells. The luciferase assay demonstrated that @entity7738 was a direct target of miR-338-3p. We also found that miR-338-3p regulated the expression levels of @entity7738 , respectively. Overexpression of miR-338-3p in @entity5 cells significantly inhibited cell proliferation, and migration. Conversely, miR-338-3p knockdown in cells with lower endogenous expression levels significantly reduced antitumor behavior. Furthermore, enforced expression of miR-338-3p led to a decline in ERK phosphorylation as well as inhibited the @entity519 induced epithelial to mesenchymal transition. Cells pre-transfected with miR-338-3p can overcome @entity519 -mediated @entity900 resistance. Taken together, we found that miR-338-3p directly targeted @entity7738 , and we provide insight into @entity5 initiation and progression, possibly representing a novel therapeutic target.

title: MicroRNA-338 inhibits migration and proliferation by targeting XXXX -induced factor 1a in nasopharyngeal carcinoma.

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['NPC', 'Nasopharyngeal cancer', 'solid tumors']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity519 :: (MESH:D000860,Disease) :: ['hypoxia']


abstract: BACKGROUND: Distinguishing stable supination-external rotation (SER) 2 from unstable SER 4 @entity1171 , using standard radiographs, is controversial. Examination under anaesthesia (EUA), @entity1642 ( @entity1642 ) and weight-bearing (WB) radiographs can aid surgical decision-making. We evaluated the effect of three methods of fracture stability assessment. METHODS: Radiographs and case-notes of 312 consecutive @entity1 with @entity13060 /4 fractures were reviewed. We recorded ankle stability assessment (plain film (PF) and EUA vs. @entity1642 vs. WB radiographs), management (conservative vs. operative), unplanned surgery and complications. RESULTS: Forty five percent assessed with @entity1642 underwent surgery (6% for PF/EUA, 4% for WB; P=0.0001). Amongst @entity1642 @entity1 , 11% underwent additional surgery (0.1% PF/EUA, 0% WB; P=0.0001). Complications occurred in 2% of the WB group (8% for PF/EUA, 22% for @entity1642 ; P=0.007). CONCLUSION: This study associates @entity1642 assessment with higher rates of surgery and complications. Subsequent studies may determine the longer term effect stability assessments have on post-traumatic @entity625 .

title: The effect of different methods of stability assessment on fixation rate and complications in supination external rotation (SER) 2/4 XXXX .

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity1171 :: ('MESH:D064386', 'Disease') :: ['ankle fractures']

entities_list: @entity1642 :: ('MESH:D015775', 'Disease') :: ['GS', 'gravity-stress']

answer: @entity1171 :: (MESH:D064386,Disease) :: ['ankle fractures']


abstract: PURPOSE: Acupuncture has been used as a complementary medical treatment for @entity4841 and other types of @entity158 . The objective of this review is to assess the effectiveness of acupuncture in the treatment of @entity4841 in @entity1 with @entity0 who were treated with aromatase inhibitors (AIs). METHODS: A literature search was performed, without language restrictions, of 10 databases from their inception through February 2014. The literature reviewed included randomized clinical trials (RCTs) and clinical trials that compared real versus sham acupuncture for the treatment of @entity85 ( @entity85 ). The methodologic quality of these trials was assessed by using the modified Jadad Quality Scale. Meta-analytic software (RevMan 5.0) was used to analyze the data. RESULTS: Five To compare the effects of real versus sham acupuncture, five RCTs were assessed by meta-analysis and quality analysis. Three of the RCTs reported favorable effects with regard to use of acupuncture in reducing @entity158 and joint-related symptoms, while the other two RCTs did not. The meta-analysis showed trends toward reduced @entity158 and @entity2693 in @entity1 given acupuncture compared with those who received sham treatment (n=82; @entity158 , mean difference: -2.07 [95% confidence interval (CI), -4.72 to 0.57]; p=0.12; @entity2693 , mean difference: -86.10 [95% CI, -249.11 to 76.92]; p=0.30), although these differences were not statistically significant. CONCLUSIONS: Acupuncture has been reported as a safe and promising treatment for @entity85 , but the present analysis indicated that the effects were not statistically significant. Other outcome measurements, such as imaging studies, would be worth including in future studies to further confirm the efficacy of acupuncture in @entity85 .

title: Acupuncture for Treating Aromatase Inhibitor-Related @entity4841 in XXXX : A Systematic Review and Meta-Analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity4841 :: ('MESH:D018771', 'Disease') :: ['arthralgia']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['AIMSS', 'AI-related musculoskeletal symptoms']

entities_list: @entity2693 :: ('MESH:C566112', 'Disease') :: ['stiffness']

answer: @entity0 :: (MESH:D001943,Disease) :: ['Breast Cancer']


abstract: PURPOSE: Acupuncture has been used as a complementary medical treatment for @entity4841 and other types of @entity158 . The objective of this review is to assess the effectiveness of acupuncture in the treatment of @entity4841 in @entity1 with @entity0 who were treated with aromatase inhibitors (AIs). METHODS: A literature search was performed, without language restrictions, of 10 databases from their inception through February 2014. The literature reviewed included randomized clinical trials (RCTs) and clinical trials that compared real versus sham acupuncture for the treatment of @entity85 ( @entity85 ). The methodologic quality of these trials was assessed by using the modified Jadad Quality Scale. Meta-analytic software (RevMan 5.0) was used to analyze the data. RESULTS: Five To compare the effects of real versus sham acupuncture, five RCTs were assessed by meta-analysis and quality analysis. Three of the RCTs reported favorable effects with regard to use of acupuncture in reducing @entity158 and joint-related symptoms, while the other two RCTs did not. The meta-analysis showed trends toward reduced @entity158 and @entity2693 in @entity1 given acupuncture compared with those who received sham treatment (n=82; @entity158 , mean difference: -2.07 [95% confidence interval (CI), -4.72 to 0.57]; p=0.12; @entity2693 , mean difference: -86.10 [95% CI, -249.11 to 76.92]; p=0.30), although these differences were not statistically significant. CONCLUSIONS: Acupuncture has been reported as a safe and promising treatment for @entity85 , but the present analysis indicated that the effects were not statistically significant. Other outcome measurements, such as imaging studies, would be worth including in future studies to further confirm the efficacy of acupuncture in @entity85 .

title: Acupuncture for Treating Aromatase Inhibitor-Related XXXX in @entity0 : A Systematic Review and Meta-Analysis.

answer: @entity4841 :: (MESH:D018771,Disease) :: ['Arthralgia']